Complimentary Webinar from the Predictive Safety Testing Consortium and Merck & Co, Inc
8th August 2017, 5 pm. BST
Presented by John-Michael Sauer, Executive Director, Predictive Safety Testing Consortium, Critical Path Institute & Xuemei Zhao, Senior Principal Scientist, Translational Molecular Biomarkers, Merck & Co., Inc.
Register today, for free: http://bit.ly/2sFP9Sg
Can’t make the dates? Still register and a copy of the recording will be sent to you
Biomarkers form a pivotal role in drug development today and as biomarkers become integrated into drug development and clinical trials, quality assurance and in particular assay validation becomes essential. There is a need for standardised guidelines for analytical methods used in biomarker measurements. Also, new biomarkers used for both the development and use of therapeutics are dependent on the establishment of a solid validation process that addresses technology integration and method validation as well as regulatory pathways for efficient biomarker development. The webinar focuses on the scientific and regulatory considerations for the analytical validation of assays in clinical trials. It will also address recent regulatory updates and the standardisation of validation procedures for efficient biomarker development.
Benefits to attending the webinar:
- Advance your knowledge on Scientific and Regulatory Considerations for Biomarker validation
- Boost your understanding of Analytical Validation of Assays Used in the Clinical Qualification of Biomarkers
Can’t make the dates? Still register and a copy of the recording will be sent to you.
For further information on how to save on your attendance and what discounts we have available please contact email@example.com
Personalize My Medicine is partnering with FindACure!
Findacure is a UK charity that builds the rare diseases community to drive research and develop treatments.
Rare diseases are defined in the EU as conditions affecting less than 1 in 2000 people — though they come much rarer than this. Because of their small patient populations, rare diseases are often assumed to be unimportant. This leads to a lack of support for patients and families, neglect by the medical profession, and little ongoing research into treatments. Findacure is here to help. We empower rare disease patient groups through a series of training programmes, and encourage collaboration between rare disease stakeholders to advance research.
Personalize My Medicine is please to announce a partnership with SMi´s 7th annual Orphan Drugs & Rare Disease conference!
7th annual Orphan Drugs and Rare Diseases UK
18th & 19th October 2017
Holiday Inn Kensington Forum, London, UK
Organisers: SMi Group
SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
Aimed at an audience of senior scientists and oncology specialists involved in targeting rare diseases therapies and drug research, Orphan Drugs UK 2017 will provide a perfect platform to discuss pioneering clinical developments and the next generation of clinical trial process. The 7th annual conference will capture expert insight through dedicated focus new therapies for different rare diseases, the importance of orphan drug development and reimbursement and repurposing.
Join us this October for strategic direction from the Rare Disease community and leverage your knowledge with the key requirements and tools for successful patient recruitment and retention through informed guidance delivered by a panel of industry experts.
- Olivier Morand, Clinical Science Program Head, Actelion Pharmaceuticals
- Larissa Kerecuk, Rare Disease Lead, Consultant Paediatric Nephrologist, Birmingham Children’s Hospital
- Oliver Timmis, CEO, AKU Society
- Stuart Hughes, Director, Head of Pharmacology, Vertex
- Nadia Assenova, Senior Director Regulatory Affairs, EMEA, Alexion Pharma GmbH
- Christine Lavery, Group Chief Executive, MPS Society
- Hsin Loke, Director, Strategy, Operations and Finance, Rare Diseases Unit, GlaxoSmithKline
- Olaf Ritzeler, External Innovation Lead, Sanofi
- Stephen Marcus, CEO, Cantex Pharmaceuticals
- Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
Exclusive highlights in 2017:
- Learn about new therapies for different rare diseases, and how these can successfully be applied to other diseases with similar attributes
- Hear what opportunities and challenges come with working on rare diseases, as well as the development of the world’s first rare disease centre for children
- Expand your knowledge on patient collaboration and patient centric models with the stream on patient engagement, covering improvement strategies, patient-led trials, and much more
- Gather further insight on drug approval and reimbursement with MAA, and how techniques for drug repurposing in the rare disease area can help treatment
We are pleased to announce that Personalize My Medicine is partnering with Oxford Global´s 2nd Annual Biomarkers & Precision Medicine USA Congress!
Oxford Global Conferences are proud to present the 2nd Annual Biomarkers & Precision Medicine USA Congress co-located with our 4th Annual Drug Discovery USA Congress, taking place on the 09-11 October 2017 in San Diego, USA.
Over 250 delegates representing leading biotech companies, global pharma organisations and internationally renowned academic institutions.
Over 40 presentations, case studies and panel discussions focused on the key issues in biomarker research, companion diagnostics, personalised medicine and clinical biomarkers.
5 Interactive Streams:
- Biomarkers in Drug Discovery and Development – Translation and Precision Medicine in Auto-Immune Diseases, CNS, Oncology, and Infectious Diseases
- Personalised Medicine, Companion Diagnostics & Patient Testing
- Innovations in Biomarker Research – Informatics, Data Management, Assay Development, Imaging Technologies
- Biomarker in Clinical Development & Clinical Trials
- Clinical Diagnostics, NGS & Genomic Markers and Genetic Testing
Free Pre-Congress Webinars
Establishing PROLIFIC, The Prognostic Lung Fibrosis Consortium
22nd June 2017, 5 pm. BST
Click here to register today, for free.
Scientific and Regulatory Considerations for the Analytical Validation of Assays for the Qualification of Biomarkers
8th August 2017, 5 pm. BST
Click here to register today, for free.
Can’t make the dates? Still register and a copy of the webinar recording will be sent to you.
If you would like to attend the congress, there is a 10% discount available (academia and pharma companies only). For further information on how to register using the discount please contact firstname.lastname@example.org
Personalize My Medicine is proud to be partnering with Genome magazine!
Genome´s vision is a world in which everyone knows the power of his or her genome. As the most trusted source of information on personalized medicine, Genome will transform the way healthcare is delivered by inspiring people to demand the care they deserve.
Genome covers personalized medicine and the genomic revolution that makes it possible. It is a quarterly magazine for the public at large: patients, family, caregivers, and healthcare professionals on the education frontlines. Its mission is to empower readers to make informed health decisions that will help them live better and longer.
Genome magazine tells compelling, in-depth, well-researched stories about the people affected by chronic and life-altering diseases, as well as the efforts to predict, prevent, diagnose, and treat those conditions.
In every issue, Genome explores complicated subjects concerning genomics and medicine — and the associated ethical, legal, and social issues — but tells those stories in a relevant, easy-to-understand manner. We also examine the issues that affect our readers on a daily basis, including personal health topics like diet, exercise, sleep, spirituality, and many more.
Personalize My Medicine is proud to be partnering with Rare Revolution magazine!
Rare Revolution is a BRAND NEW digital magazine giving a voice to patients affected by RARE conditions and the charities that represent and support them.
Personalize My Medicine is proud to be partnering with Cambridge Rare Disease Network (CRDN)!
CRDN’s vision is for a world where people with rare diseases are valued, celebrated, and supported through life’s journey. Our mission is to help create regional grassroots networks of people and families affected by rare diseases and to support the patient journey and their common concerns. We are creating an active patient and family roundtable identifying and addressing key pain points and an active companies forum to raise funding and potentially solve key pain points for companies working in the rare disease space. We host a range of academic and community projects and events to bring together key stakeholders to share, learn and collaborate.
Personalize My Medicine is proud to announce a partnership with One HealthTech!
One HealthTech is a network that supports and promotes women and other under-represented groups in health innovation. OHT acknowledges and champions the need and importance for better inclusion of all backgrounds, skill sets, and disciplines in health and technology.
OHT aims to include different perspectives in healthcare design, in order to build a health system that works for everyone and supports its members through education, mentorship, promoting the positive effects of inclusion in technology, encouraging broader participation at meetings and events, championing diversity in leadership and having fun!